Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis

Review Rheumatology

Socioeconomic Status and Medication Use in Rheumatoid Arthritis: A Scoping Review

Oscar Russell et al.

Summary: This article, using a scoping review approach, identified that socioeconomic status (SES) affects medication use in rheumatoid arthritis (RA) patients. However, the use of different SES definitions hinders comparisons between studies.

ARTHRITIS CARE & RESEARCH (2023)

Add to Collection

Article Medicine, General & Internal

Uptake of biosimilar drugs in Canada: analysis of provincial policies and usage data

Alison R. McClean et al.

CANADIAN MEDICAL ASSOCIATION JOURNAL (2022)

Add to Collection

Article Health Policy & Services

Trends in Canadian prescription drug purchasing: 2001-2020

Mark Hofmeister et al.

Summary: This study aims to describe the largest expenditures by medication class over time in outpatient and inpatient settings in Canada. The findings reveal that infliximab is the top expenditure in the outpatient setting, while pembrolizumab is the top expenditure in the inpatient setting. This study is of great importance for guiding policies to control prescription medication expenditures.

JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE (2022)

Add to Collection

Article Rheumatology

Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept-a cohort study in British Columbia

Anat Fisher et al.

Summary: This study aimed to detect early impacts on health services utilization following a mandated switch from originator to biosimilar etanercept in British Columbia, Canada. The results showed that only transient and/or anticipated increases in drug refills and physician visits were observed during the study period.

BMC RHEUMATOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Physician, Practice, and Patient Characteristics Associated With Biosimilar Use in Medicare Recipients

Emma Boswell Dean et al.

Summary: This study found that practice setting and hospital ownership status were closely associated with the use of biosimilars in the Medicare population, with different patterns observed for different drug classes. Further research is needed to understand the reasons for these differences across drug classes.

JAMA NETWORK OPEN (2021)

Add to Collection

Article Pharmacology & Pharmacy

Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure

Sabine Vogler et al.

Summary: "The article discusses different policy measures implemented by European countries to shape the biologicals market and explores potential savings from increased use of biosimilar medicines in Germany. Various pricing policies, reimbursement strategies, and demand-side policies impact the uptake and cost savings of biosimilar medicines in different countries. Monitoring and evaluating the impact of these policies is essential for a comprehensive understanding of their effectiveness in achieving cost savings and increasing access to affordable healthcare."

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy